The FAMHP is launching a new dashboard with up-to-date figures on clinical trials in Belgium. With this initiative, the agency aims to increase transparency and further support the clinical research sector.
The FAMHP is strongly committed to strengthening the clinical trials sector in Belgium. For example, in 2026, shortened timelines were introduced for processing applications for all initial submissions of mononational clinical trials. Belgium also takes part in the FAST-EU initiative, which investigates the possibility of reducing the turnaround time between submission and decision for multinational clinical trials to 70 days.
In addition to these initiatives, the FAMHP also aims to increase visibility and transparency. It is for that reason that the agency is launching the new dashboard clinical trials.
This dashboard is updated quarterly and contains up-to-date figures on all initial clinical trial submissions under the Clinical Trials Regulation (CTR) for which a decision has been made in Belgium since the entry into force of this regulation. This provides stakeholders and the general public with a clear and reliable overview of the number of clinical trials submitted in Belgium.
The dashboard also provides insight into the different phases of clinical trials, the therapeutic areas within which research takes place and the median turnaround times to a decision per phase of clinical research.
For example, the data show that:
- the median turnaround time from submission to decision for a phase 1 mononational clinical trial in 2025 is 41 days, based on 42 trials submitted in this category;
- the number of clinical trial applications in 2025 decreased compared to 2024, but the number of fully approved trials (without conditions) increased from 225 to 289;
- about 30% of clinical trials in 2025 focus on cancer therapies.
These are just some of the insights that can be derived from the dashboard. Discover all the figures and analyses at www.dashboard-clinicaltrials.be.